Biosimilars Market Size & Share 2026-2035
Download Free PDF
Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy and data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Revenue share analysis
1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Product trends
2.2.3 Application trends
2.2.4 Manufacturing type trends
2.2.5 Technology trends
2.2.6 Distribution channel trends
2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising chronic disease burden
3.2.1.2 Increasing biologics patent expirations
3.2.1.3 Higher clinician and patient acceptance
3.2.2 Industry pitfalls and challenges
3.2.2.1 Limited market penetration in some regions
3.2.2.2 High development and manufacturing costs
3.2.3 Market opportunities
3.2.3.1 Advancement in AI?driven bioprocessing
3.2.3.2 Adoption of streamlined regulatory pathways
3.3 Growth potential analysis
3.4 Regulatory landscape (Driven by primary research)
3.4.1 North America
3.4.2 Europe
3.4.3 Asia Pacific
3.4.4 Latin America
3.4.5 MEA
3.5 Technology landscape
3.5.1 Current technology
3.5.2 Emerging technologies
3.6 Reimbursement landscape
3.6.1 U.S.
3.6.2 Canada
3.6.3 Europe
3.6.4 Australia
3.6.5 New Zealand
3.7 Biosimilar litigiation landscape
3.8 Future market trends (Driven by primary research)
3.9 Impact of AI and generative AI on the market (Driven by primary research)
3.10 Bisomilar factor analysis
3.10.1 Access
3.10.2 Regulations
3.10.3 Payer assessment and access
3.10.4 Physician acceptance
3.10.5 Patient acceptance
3.11 Biosimilar product pipeline analysis
3.12 Biosimilars approval scenario, 2022 - 2025
3.13 Biologics patent expiry scenario
3.14 International policies on use of biosimilar drugs
3.14.1 Interchangeability, switching and subsitution
3.14.2 Supply side policies
3.14.3 Prescribing incentives
3.15 Porter's analysis
3.16 PESTEL analysis
Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.2.3 Asia Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2022-2035 ($ Mn)
5.1 Key trends
5.2 Recombinant non-glycosylated proteins
5.2.1 Human growth hormone
5.2.2 Granulocyte colony-stimulating factor (filgrastim)
5.2.3 Insulin
5.2.4 Interferon
5.2.4.1 Alfa
5.2.4.2 Beta
5.3 Recombinant glycosylated proteins
5.3.1 Monoclonal antibodies
5.3.1.1 Infliximab
5.3.1.2 Rituximab
5.3.1.3 Adalimumab
5.3.1.4 Trastuzumab
5.3.1.5 Bevacizumab
5.3.2 Erythropoietin
5.3.2.1 Alfa
5.3.2.2 Beta
5.3.3 Follitropin
5.3.3.1 Alfa
5.3.3.2 Beta
5.3.4 Fusion proteins
5.4 Other products
Chapter 6 Market Estimates and Forecast, By Application, 2022-2035 ($ Mn)
6.1 Key trends
6.2 Hematology
6.2.1 Neutropenia
6.2.2 Anemia
6.2.3 Other hematology applications
6.3 Oncology
6.3.1 Lung cancer
6.3.2 Brain cancer
6.3.3 Breast cancer
6.3.4 Cervical cancer
6.3.5 Colorectal cancer
6.3.6 Leukemia
6.3.7 Other Oncology applications
6.4 Autoimmune disease
6.4.1 Arthritis
6.4.1.1 Rheumatoid arthritis
6.4.1.2 Psoriatic arthritis
6.4.1.3 Juvenile arthritis
6.4.1.4 Ankylosing spondylitis
6.4.1.5 Other arthritis
6.4.2 Inflammatory bowel disease (IBD)
6.4.2.1 Ulcerative colitis
6.4.2.2 Crohn's disease
6.4.2.3 Other IBD
6.4.3 Psoriasis
6.4.4 Other autoimmune diseases
6.5 Ophthalmology
6.6 Growth hormone deficiency
6.7 Diabetes
6.8 Other applications
Chapter 7 Market Estimates and Forecast, By Manufacturing Type, 2022-2035 ($ Mn)
7.1 Key trends
7.2 Contract research and manufacturing services
7.3 In-house
Chapter 8 Market Estimates and Forecast, By Technology, 2022-2035 ($ Mn)
8.1 Key trends
8.2 Recombinant DNA technology
8.3 Mammalian cell culture systems
8.4 Other technologies
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022-2035 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Specialty pharmacies
9.4 Other distribution channels
Chapter 10 Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
Chapter 11 Company Profiles
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at [email protected]
Share Content
Add Citations
Monali Tayade. 2026, August. Biosimilars Market - By Product, By Application, By Manufacturing Type, By Technology, By Distribution Channel – Growth Forecast, 2026 – 2035 (Report ID: GMI3328). Global Market Insights Inc. Retrieved September 4, 2026, from https://www.gminsights.com/toc/details/biosimilars-market
Biosimilars Market
Get a free sample of this report
Biosimilars Market Size
The biosimilars market is valued at USD 38.7 billion in 2025 and is projected to reach USD 46.4 billion by 2026, expanding at a 16.6% CAGR. The market is also estimated at USD 185.2 billion in 2035. Growth rests on a widening set of biologic reference products, but the commercial result is determined less by patent expiry alone than by whether manufacturers can convert analytical comparability, scalable production, and formulary access into uptake.
Biosimilars are biological products shown to be highly similar to a reference product, with no clinically meaningful differences in safety, purity, or potency. U.S. approvals occur under an abbreviated statutory pathway, while the EU has operated a dedicated biosimilar framework since 2004 and approved its first biosimilar in 2006.[1]Those pathways matter commercially because they permit a development program centered on comparative evidence rather than repetition of the originator's full clinical-development program.
The economics are visible in reimbursed care. Medicare Part B biosimilar competition reduced program spending by $12.9 billion between 2018 and 2023, including $4.4 billion in 2023, and lowered out-of-pocket costs by nearly $2,000 per beneficiary annually.[3] Demand is concentrated in biologic-intensive care: GLOBOCAN recorded about 20 million new cancer cases in 2022,[4] the IDF estimates 589 million adults aged 20–79 were living with diabetes in 2024,and rheumatoid arthritis affected 17.6 million people in 2020.[6] These are not interchangeable demand pools: infusion oncology, chronic self-administered immunology, and insulin dispensing each face different procurement and substitution conditions.
GMI Analyst View
The market's projected expansion is best understood as a shift toward more commercially consequential, technically demanding molecules rather than a simple extension of early filgrastim and erythropoietin competition. Glycosylated proteins already account for 67.6% of 2025 revenue, so mammalian-cell capability, glycan characterization, and evidence packages that support payer confidence will increasingly determine which developers can participate in large opportunities. The resulting market should remain more concentrated than small-molecule generics even as treatment volumes rise.
Savings evidence also exposes the central tension. Biosimilar competition can reduce public spending materially, but a low-cost product does not automatically obtain formulary preference or switching acceptance. Manufacturers with both reliable supply and access capabilities are therefore positioned to capture more value than firms that treat regulatory approval as the endpoint.
Key Drivers
Patent expiries broaden the addressable molecule set Loss of exclusivity creates the legal opening for competition, but development decisions concentrate on reference products with sufficient revenue, patient volume, and durable treatment use to absorb the cost of comparability studies and process scale-up. This favors immunology and oncology antibodies, as well as established supportive-care products, over lower-volume biologics. The commercial effect is a pipeline that follows the economic quality of each reference market rather than the calendar of expiries alone.
Regulatory refinement reduces avoidable development burden The FDA's review framework distinguishes biosimilar approval from an interchangeability determination, and its materials describe how comparative analytical, nonclinical, and clinical evidence supports those decisions.The EMA's tailored-clinical-approach reflection paper similarly examines when a more focused clinical program may be scientifically justified.[7] Such evolution is significant for complex antibodies: lower unnecessary trial burden can redirect capital toward multiple candidates, provided manufacturing comparability remains robust.
Reimbursement pressure converts biosimilars into a budget-management tool Public payers have a direct reason to favor competition where biologics dominate treatment budgets. Medicare's spending reduction after biosimilar entry is particularly relevant to provider-administered products, where reimbursement policy and institutional purchasing can drive switching at scale.In Europe, tendering, prescribing targets, and substitution practices have produced highly differentiated uptake by country and molecule, demonstrating that policy design affects realized competition as much as the number of approved products.[8]
Disease burden sustains the treated population Cancer, diabetes, and immune-mediated disease support demand across distinct biosimilar classes. Global cancer incidence is projected to rise to 35 million new cases annually by 2050,while diabetes is projected to affect 853 million adults by 2050.Inflammatory bowel disease incidence increased 88.3% globally between 1990 and 2021.[9] These trends expand the potential treated population, but they also increase the value of channels that can maintain continuity of care during switches.
Advanced bioprocessing expands feasible development targets Recombinant DNA platforms remain the foundation of biologics production; mammalian systems add the process control required for many glycosylated proteins. Process analytics, high-resolution characterization, and improved cell-culture productivity can reduce uncertainty during comparability work. Their strategic value lies less in a generic productivity claim than in enabling developers to select difficult molecules without accepting unmanageable batch-consistency risk.
Key Restraints
Patent litigation can separate approval from launch A biosimilar may receive regulatory approval yet remain commercially constrained by patent disputes and settlement timing. This creates a planning problem beyond legal expense: manufacturing capacity, commercial hiring, and inventory must be committed before the effective launch date is fully certain. The risk is greatest for high-value antibodies, where several developers may pursue the same opportunity and a delayed launch can erase a first-mover advantage.
Formulary economics can blunt lower list prices In U.S. self-administered categories, pharmacy benefit manager contracting can favor a reference brand or a limited number of biosimilars. The practical outcome is that manufacturers must offer a proposition that works for the plan, specialty pharmacy, prescriber, and patient simultaneously. An approved product without preferred placement may therefore have less commercial effect than a later entrant with superior contracting terms.
Capital intensity narrows the development field Complex biosimilars require characterization, process development, clinical pharmacology, regulatory work, and commercial-scale supply. The fixed-cost burden makes it rational to pursue large reference markets and discourages programs for smaller or rare-disease products. That concentration supports near-term revenue growth in large categories but limits the breadth of access gains across biologics.
Clinical switching acceptance remains product- and setting-specific Regulatory approval establishes a scientific standard; it does not remove every operational objection to switching a stable patient. Acceptance depends on specialty practice norms, patient communication, product presentation, and reimbursement rules. In hospital-administered care, formulary committees can standardize a transition. In chronic ambulatory immunology, confidence and benefit design may carry more weight, which makes education and service continuity commercial requirements rather than ancillary activities.
Cross-market regulatory differences add execution cost The FDA, EMA, PMDA, NMPA, CDSCO, and other authorities share a comparability-based concept but apply it through different processes and local expectations. A global developer must coordinate reference-product sourcing, dossiers, manufacturing-site inspections, and market-specific evidence requirements. This makes regulatory sequencing a portfolio decision, not an administrative afterthought.
GMI Analyst View
The durable growth drivers and the binding constraints act at different points in the value chain. Disease burden and biologic expiries create opportunity upstream; litigation, manufacturing economics, and payer access determine whether that opportunity becomes a launch; switching behavior determines whether a launch becomes sustained volume. This sequence explains why the number of approvals is an incomplete indicator of market maturity.
Biosimilars Market Segment Analysis
By Product
By Application
By Manufacturing Type & Technology
By Distribution Channel
GMI Analyst View
Segment growth is not evenly distributed between technically complex and commercially accessible products. Glycosylated proteins generate the largest value pool, yet the non-glycosylated segment posts the highest product growth rate because established protein categories can scale through familiar production and dispensing models. Hospital procurement can accelerate uptake in hematology and infusion oncology, while autoimmune disease and diabetes require success in specialty dispensing and patient-level transitions.
Biosimilars Market Regional Analysis
Europe
Europe is the largest regional market, at $15,215.0 million and 39.3% of global value in 2025, and is projected to reach $69,760.8 million in 2035. Its lead reflects long-standing EMA regulation and national approaches to tendering, prescribing, and substitution across Germany, the UK, France, Spain, Italy, and the Netherlands.[2]
North America
North America represents $11,585.4 million in 2025, or 29.9% of the global market, and reaches $54,883.6 million in 2035 at a 16.5% CAGR. The U.S. contributes $10,291.7 million (88.8% of regional revenue) and is projected to reach $48,441.0 million, supported by increasing approval volumes and Medicare savings. Canada contributes $1,293.7 million in 2025 and reaches $6,442.5 million.
Asia Pacific
Asia Pacific grows fastest at 17.4% CAGR, from $10,367.7 million in 2025 to $52,818.1 million in 2035. Japan maintains an established biosimilar framework under the PMDA,[10] while India, South Korea, China, and Australia combine deep local manufacturing capacity with expanding patient access.
Latin America
Latin America grows from $1,096.6 million in 2025 to $5,431.4 million in 2035, led by Brazil, Mexico, and Argentina. Growth is driven by public tenders seeking cost-effective alternatives to originator biologics.
Middle East & Africa
The Middle East & Africa accounts for $471.2 million in 2025 and reaches $2,290.4 million in 2035, anchored by healthcare modernization in South Africa, Saudi Arabia, and the UAE.
GMI Analyst View
Regional divergence is fundamentally a policy-and-procurement story. Europe's 39.3% share reflects the accumulated effect of centralized scientific review combined with national mechanisms that make switching executable. North America has strong economic incentives but remains subject to formulary contracting dynamics, while Asia Pacific's 17.4% CAGR provides the strongest long-term volume runway.
Biosimilars Market Share & Competitive Landscape
The competitive core consists of Sandoz, Pfizer, Amgen, Celltrion, and Biocon, which collectively hold approximately 55% of global market share in 2025. Scale is valuable because biosimilar competition requires capabilities that are difficult to assemble independently: analytical development, biologics manufacturing, regulatory execution, medical support, and market access.
Recent Industry Developments
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.